Abstract Library

#3787 PRESTO 3 – An international, simulated-use study to assess nurses’ preferences between two lanreotide injection syringes (Somatuline Autogel vs Pharmathen) for patients with neuroendocrine tumors (NETs) and/or acromegaly

Introduction: Somatostatin analogues (SSAs) are often used to treat patients with NETs and acromegaly. The Pharmathen syringe is now available in Europe and the USA for depot injection. It is important for decision making when using SSAs that there is confidence in and ease of use with any syringe.

Conference:

Presenting Author: Ferone D

Authors: Grossman A, Martin W, Williams J, Houchard A, Pommie C,

Keywords: Gastroenteropancreatic neuroendocrine tumor, Simulated use study, Somatostatin analogues, User preference,

#2932 Evaluation of Nurse Preferences between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe: An International Simulated Use Study (PRESTO)

Introduction: A new lanreotide autogel/depot (LAN) syringe was developed based on feedback from a human factors study to improve user experience.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Truong Thanh X, Adelman D, Feuilly M, Houchard A, Cella D,

Keywords: Somatuline lanreotide, syringe, neuroendocrine tumors, medical treatment,

#1646 Patient Satisfaction Regarding Home Injection Service for Somatostatin Analogues: A Survey Among Patients with a Neuroendocrine Tumour

Introduction: Depot somatostatin analogues (SSA) Sandostatin LAR® (SL) and Somatuline Autogel® (SA) injections, are facilitated by a professional home injection service.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Geilvoet W, Feelders R, de Herder W,

Keywords: somatostatin analogues, home injection,

#1488 Chemoprevention with a Long Acting Somatostatin Analogue in a Multiple Endocrine Neoplasia Type 1 (MEN1) Knockout Mouse Model Does Delay the Progression of Pancreatic Neuroendocrine Neoplasms (pNENs)

Introduction: Long acting somatostatin analogues (LAR) are an essential part of the treatment of neuroendocrine tumours.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lopez C

Authors: Lopez C, Bartsch D, Albers M, Bollmann C, Roth S,

Keywords: chemoprevention, neuroendocrine neoplasms, somatostatin analogue ,

#1284 Pharmacokinetic (PK) Differences Between Subcutaneous and Intramuscular Administration of Lanreotide: Results from a Phase I Study

Introduction: Data have shown that 38% of intended gluteal intramuscular (IM) injections with long-acting release octreotide were mistakenly given subcutaneously (SC); in carcinoid syndrome patients, this significantly increased the rate of flushing (P=0.005; Boyd 2013, Pancreas). Lanreotide depot(LD) recently became FDA-approved for the treatment of gastroenteropancreatic neuroendocrine tumors (120 mg Q4W) as a deep SC injection.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Manon A

Authors: Manon A, Wolin E, Chassaing C, Lewis A, Bertocchi L,

Keywords: lanreotide, Somatuline, pharmacokinetic, PK,